GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
Businesswire·2025-12-02 16:43
Core Insights - GenSight Biologics has received authorization from the French medicines safety agency ANSM to conduct the dose-ranging study REVISE, aimed at investigating the efficacy of its gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1] Company Overview - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies [1] - The company specializes in treatments for retinal neurodegenerative diseases and central nervous system disorders [1]